Adam Walsh
Stock Analyst at Roth MKM
(1.14)
# 3,876
Out of 5,118 analysts
152
Total ratings
39.9%
Success rate
-1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $41 | $10.35 | +296.14% | 11 | Nov 6, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $25 | $5.34 | +368.16% | 6 | Nov 6, 2026 | |
| OSTX OS Therapies | Reiterated: Buy | $7 → $6 | $1.00 | +500.00% | 7 | Nov 5, 2026 | |
| INSM Insmed | Reiterated: Buy | $198 → $204 | $114.41 | +78.31% | 25 | Oct 29, 2026 | |
| DNTH Dianthus Therapeutics | Initiated Coverage: Buy | $113 | $86.03 | +31.35% | 1 | Oct 27, 2026 | |
| EQ Equillium | Reiterated: Buy | $12 | $1.51 | +694.70% | 14 | Oct 27, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $21.03 | +175.80% | 8 | Oct 21, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Buy | $70 → $82 | $15.43 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $256.82 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Reiterated: Buy | $298 | $33.45 | n/a | 9 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $72.77 | n/a | 8 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $71 | $3.73 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $25 | $0.6337 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $132.04 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $547.09 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $56.03 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $221.37 | $11.56 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $155.94 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $17.82 | n/a | 2 | May 20, 2015 |
Arcturus Therapeutics Holdings
Nov 6, 2026
Reiterated: Buy
Price Target: $41
Current: $10.35
Upside: +296.14%
BioAge Labs
Nov 6, 2026
Reiterated: Buy
Price Target: $25
Current: $5.34
Upside: +368.16%
OS Therapies
Nov 5, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $1.00
Upside: +500.00%
Insmed
Oct 29, 2026
Reiterated: Buy
Price Target: $198 → $204
Current: $114.41
Upside: +78.31%
Dianthus Therapeutics
Oct 27, 2026
Initiated Coverage: Buy
Price Target: $113
Current: $86.03
Upside: +31.35%
Equillium
Oct 27, 2026
Reiterated: Buy
Price Target: $12
Current: $1.51
Upside: +694.70%
vTv Therapeutics
Oct 21, 2026
Reiterated: Buy
Price Target: $58
Current: $21.03
Upside: +175.80%
Ultragenyx Pharmaceutical
May 18, 2020
Reiterated: Buy
Price Target: $70 → $82
Current: $15.43
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $256.82
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Reiterated: Buy
Price Target: $298
Current: $33.45
Upside: n/a
Feb 10, 2020
Reiterated: Hold
Price Target: n/a
Current: $72.77
Upside: n/a
Nov 12, 2019
Reiterated: Buy
Price Target: $71
Current: $3.73
Upside: n/a
Jun 25, 2019
Reiterated: Buy
Price Target: $36 → $25
Current: $0.6337
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $132.04
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $547.09
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $56.03
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $221.37
Current: $11.56
Upside: n/a
Jun 24, 2015
Reiterated: Buy
Price Target: $160
Current: $155.94
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $17.82
Upside: n/a